{"entity":{"id":"adaptive-immune-resistance","kind":"term","name":"Adaptive immune resistance","aka":["adaptive immune resistance","interferon-induced PD-L1","IFN-gamma-induced PD-L1","induced PD-L1 expression"],"tldr":"An immune attack can induce its own restraint: signals from responding T cells raise inhibitory proteins on nearby cells. This induced defence differs from resistance acquired after a treatment response.","summary":"The sequence proposed by Taube and colleagues and mapped in more detail since is a loop. A T cell recognises a tumour peptide on HLA and releases interferon gamma; the interferon acts through the Janus kinases JAK1 and JAK2 in nearby tumour and immune cells; PD-L1 rises; PD-L1 binds PD-1 on the T cell and damps it. In melanoma cell lines, Garcia-Diaz and colleagues found that the interferon gamma, JAK1 and JAK2, STAT1, STAT2 and STAT3, IRF1 axis primarily regulates PD-L1, with IRF1 binding the PD-L1 promoter, and biopsies from patients with melanoma showed enrichment of that interferon signature and of STAT and IRF1 target genes in tumours that responded to anti-PD-1 treatment.\n\nPD-L1 is not the only brake that follows the attack. Spranger and colleagues found in human melanoma that the T-cell-inflamed tumours were the ones with high indoleamine 2,3-dioxygenase (IDO), PD-L1 and regulatory T cells, and in mice that all three depended on CD8 T cells being present: IDO and PD-L1 through interferon gamma, and regulatory T cells through CCR4-binding chemokines with some induced proliferation. Their reading was that these pathways are driven by the immune response rather than orchestrated by the cancer cells.\n\nEvidence from tissue. In human melanocytic lesions, 98% of PD-L1-positive (B7-H1-positive) tumours had tumour-infiltrating lymphocytes compared with 28% of PD-L1-negative tumours; positive melanocytes sat almost always immediately next to lymphocytes, and interferon gamma was detected at the interface but not in PD-L1-negative tumours (Taube and colleagues). The same colocalisation appeared in inflamed benign naevi, which fits PD-L1 as a response to tissue inflammation. In triple-negative breast cancer, Gruosso and colleagues described an immunoreactive group whose tumours had granzyme B-positive CD8 T cells inside cancer-cell regions, a type 1 interferon signature and elevated IDO and PD-L1, the pattern adaptive resistance predicts; that is an association in tissue and not a direct test of the loop. The alternative, called innate or constitutive resistance, is PD-L1 driven by the cancer cell's own signalling regardless of T cells.\n\nA functionally important loss of JAK1 or JAK2 can impair the tumour cell response to interferon gamma. In four people with metastatic melanoma that relapsed on anti-PD-1 treatment, two relapse samples carried loss-of-function JAK1 or JAK2 mutations with deletion of the remaining normal allele, and truncating JAK1 or JAK2 mutations left the cells unresponsive to interferon gamma (Zaretsky and colleagues). The JAK2-deficient relapse cells lost interferon-gamma-induced PD-L1 and class-I increases but retained responses to interferon alfa and beta. In engineered melanoma cells, JAK1 or JAK2 loss did not abolish recognition by the tested NY-ESO-1-specific T cells. Loss of inducibility is therefore different from absence of all baseline recognition. This selected series does not estimate a frequency for all cancers.","asOf":"2026-11-11","links":[{"label":"Taube et al., colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape (Sci Transl Med 2012)","url":"https://pubmed.ncbi.nlm.nih.gov/22461641/"},{"label":"Garcia-Diaz et al., interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression (Cell Rep 2017)","url":"https://pubmed.ncbi.nlm.nih.gov/28494868/"},{"label":"Spranger et al., up-regulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells (Sci Transl Med 2013)","url":"https://pubmed.ncbi.nlm.nih.gov/23986400/"},{"label":"Gruosso et al., spatially distinct tumor immune microenvironments stratify triple-negative breast cancers (J Clin Invest 2019)","url":"https://pubmed.ncbi.nlm.nih.gov/30753167/"},{"label":"Zaretsky et al., mutations associated with acquired resistance to PD-1 blockade in melanoma (N Engl J Med 2016)","url":"https://pubmed.ncbi.nlm.nih.gov/27433843/"}],"tags":[],"related":["pd1-checkpoint","pdl1","pd1","ido1","jak1","jak2","stat1","irf1","interferon-gamma-signature","cold-vs-hot","resistance","cancer-immunity-cycle","paper-tumeh-pd1-adaptive-immune-resistance-nature-2014","immune-exclusion"],"cancers":[],"sections":[],"technologies":[],"targets":["pdl1","pd1","ido1","jak1","jak2","stat1","irf1"],"drugs":[],"companies":[],"institutions":[],"pathways":["pd1-checkpoint","cancer-immunity-cycle"],"terms":["interferon-gamma-signature","cold-vs-hot","resistance"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-tumeh-pd1-adaptive-immune-resistance-nature-2014"],"journals":[],"dependsOn":[],"notes":["Reading the label. PD-L1-positive does not mean the tumour is suppressing the immune system on its own, because in adaptive resistance the signal is a reaction to T cells. PD-L1-negative does not mean no immune attack: staining is patchy, assays differ and other brakes exist. Adaptive resistance also differs from acquired resistance, which means a tumour that responded to treatment and then stopped responding; here 'adaptive' names an induced defence, and the two can overlap without being the same thing.","A PD-L1 stain measures protein on defined tumour and immune cells, not why it is present. Colocalization with lymphocytes and interferon-related expression can support induced expression, while a uniform lymphocyte-poor pattern raises other hypotheses; neither pattern proves a cause. Adding interferon gamma and measuring PD-L1 tests inducibility in a laboratory model. Appropriate pathway perturbations and controls investigate causation, and neither that assay nor a tissue score measures the entire in-vivo feedback loop or treatment benefit.","In a fictional biopsy, PD-L1 is found at a lymphocyte-rich border but not at the centre. That distribution is consistent with induced expression; it does not prove the proposed loop. A negative region does not establish absence of immune attack elsewhere, and other inhibitory pathways may operate. A positive PD-L1 result alone also cannot distinguish induced from constitutive expression.","What the loop means for treatment is a hypothesis to test. PD-1 and PD-L1 drugs interrupt the last step, the binding of PD-L1 to PD-1. Spranger and colleagues argued that checkpoint approaches might be preferentially beneficial for patients with a pre-existing T-cell-inflamed microenvironment, which is a reading of their data and not a trial result."],"category":"Immunology"},"route":"/terms/adaptive-immune-resistance/","neighbours":{"pathway":[{"id":"immune-desert-exclusion","kind":"pathway","name":"Cold tumours: immune deserts and exclusion","route":"/pathways/immune-desert-exclusion/"},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"},{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"target":[{"id":"ido1","kind":"target","name":"IDO1","route":"/targets/ido1/"},{"id":"irf1","kind":"target","name":"IRF1","route":"/targets/irf1/"},{"id":"jak1","kind":"target","name":"JAK1","route":"/targets/jak1/"},{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"stat1","kind":"target","name":"STAT1","route":"/targets/stat1/"}],"term":[{"id":"cd4-t-cell-subsets","kind":"term","name":"CD4 T-cell subsets","route":"/terms/cd4-t-cell-subsets/"},{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/"},{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/"},{"id":"immune-exclusion","kind":"term","name":"Immune exclusion","route":"/terms/immune-exclusion/"},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/"},{"id":"interferon-gamma-signature","kind":"term","name":"Interferon-gamma gene signature (T-cell-inflamed signature)","route":"/terms/interferon-gamma-signature/"}],"paper":[{"id":"paper-tumeh-pd1-adaptive-immune-resistance-nature-2014","kind":"paper","name":"Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge","route":"/key-papers/paper-tumeh-pd1-adaptive-immune-resistance-nature-2014/"}]}}